Recent Updates
Recently added Catalysts

Primidone

Phase 1

Healthy | Small molecule | Other |Dr. Reddy's Laboratories Ltd|Last Updated: May 27, 2010

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment24
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01132040Bioequivalence Study of Primidone Tablets 50 mg of Dr. Reddy's Under Fasting ConditionsPHASE1 COMPLETED 24Aug 1, 2006Sep 1, 2006May 27, 20101 India
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Bioequivalence based on Cmax and AUC parameters
2 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
PrimidoneEXPERIMENTALPrimidone Tablets, USP 50 mg of Dr. Reddy's Laboratories
MysolineACTIVE_COMPARATORMysoline Tablets of Yamanouchi Pharma Technologies Inc,
Interventions
NameTypeDescription
PrimidoneDRUGPrimidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: Subjects must fulfill all of the following criteria to be considered for inclusion into this study: 1. Subjects who will provide written informed consent. 2. Subjects must be healthy, adult, human beings within 18-45 years of age (both inclusive)weighing at least 50 kg. 3. Havi...

Countries:India
Unlock Eligibility Criteria